Modest growth forecast for global hepatitis B market

The value of the global hepatitis B virus (HBV) therapeutics market will increase modestly over the next 6 years, from almost $3 billion in 2014 to $3.5 billion by 2021, representing a compound annual growth rate (CAGR) of 2.3%, a new study forecasts.

According to business intelligence provider GBI Research, this rise will occur across the eight major markets of the USA, Canada, the UK, France, Germany, Italy, Spain and Japan, and will be primarily driven by increasing immigration from medium and high-prevalence countries.

GBI Research analyst Priyatham Salimadugu says: “The US, which has one of the largest shares of the HBV treatment market, sees considerable migration from high-prevalence countries, such as the Philippines, China, and Vietnam. While immigration will enlarge the patient pool, HBV treatment market expansion will be restricted by prophylactic vaccination in the US and much of Europe.”